- Lunasin is the first nutritional compound identified to affect gene expression and promote optimal health at the epigenetic level.
- LunaRich® from Reliv optimizes bioactive lunasin more than any other source available today.
- Reliv owns exclusive rights to LunaRich and holds three lunasin-related patents:
- A patent on lunasin’s mechanism of action for reducing LDL cholesterol in the body (2 patents pertaining to this).
- A composition of matter patent on Reliv’s LunaRich technology as it relates to its superior ability to deliver bioactive lunasin to the body. Reliv uses a process that is chemical free and preserves the protein matrix that chaperones the lunasin peptide through the digestive system and provides greater bioavailability. No one else has this technology.
Health Benefits of Lunasin (PDF)
1997-2012: Fifteen Years of Research on Peptide Lunasin
Recognized by the American Heart Association! Circulation
Need Proof? LunaRich marks the culmination of an extensive research and development process that began with the discovery of the lunasin peptide in 1996. It is now one of the most heavily researched and scientifically supported nutritional compounds available today.
• 30+ Research institutions • 20+ Funding sources • 100+ Published papers
LunaRich elevates Reliv to a unique status in the nutrition industry. Reliv now owns an ingredient in its entirety, from the extraction process to the patented mechanisms of action within the body. And LunaRich isn’t just any ingredient; it’s the world’s first epigenetic superfood.
Reliv has always endeavored to remain on the cutting edge of nutrition science in formulating products. With the acquisition of lunasin, Reliv is now leading the industry in the budding field of nutritional epigenetics. New research shows that through nutrition people can influence which genes are expressed. Reliv is committed to building on this emerging science and developing nutritional solutions with lunasin and other plant-based nutrients that help people take control of their health.